Torbay Pharmacy Manufacturing Unit appoints md

Dr Nick Frampton to run the unit

The UK’s South Devon Healthcare NHS Foundation Trust has appointed Dr Nick Frampton as managing director of the Torbay Pharmacy Manufacturing Unit (PMU), which produces licensed pharmaceuticals, pharmaceutical specials and medical devices.

Frampton joins the firm from Advanced Medical Solutions Group, where he was vice president of sales and marketing and contributed to a period of double-digit growth. He has formerly held quality, technical and commercial roles at West Pharmaceutical Services, Ernest Jackson and Banner Pharmacaps.

You may also like

Finance
NorthEdge invests in sterile injectable CMO to accelerate international growth

NorthEdge invests in sterile injectable CMO to accelerate international growth

Private equity firm NorthEdge has invested in sterile injectable contract manufacturer and licence holder, Torbay Pharmaceuticals (Torbay), to support its next phase of international growth
Manufacturing
DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction

DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction

The pair will combine DNA Script's EDS technology with GE HealthCare's DNA scaling technology to create a faster, more flexible manufacturing process for cell-free DNA as the use of personalised and time-sensitive genetic medicines grows
Research & Development
Digitalisation: more space for research and development in Salzburg, Austria

Digitalisation: more space for research and development in Salzburg, Austria

COPA-DATA is investing €15 million in the project, underlining its long-term commitment to Salzburg and Austria as a location for technology, research and innovation
Finance
Ratio Therapeutics raises $70m to expand radiopharmaceutical manufacturing

Ratio Therapeutics raises $70m to expand radiopharmaceutical manufacturing

The Series C financing will support clinical development of Ratio’s Ac-225 radiotherapeutic pipeline and expansion of its radiopharmaceutical manufacturing infrastructure
Finance
AstraZeneca-BMS $400bn merger could reshape US pharma manufacturing

AstraZeneca-BMS $400bn merger could reshape US pharma manufacturing

A potential AstraZeneca acquisition of Bristol Myers Squibb would create a near-$400bn pharma giant, combining major oncology portfolios and extensive US manufacturing operations
Finance
Clean Cells expands biopharma analytics with Anaquant acquisition

Clean Cells expands biopharma analytics with Anaquant acquisition

The purchase adds mass spectrometry-based protein characterisation and HCP analysis to Clean Cells’ GMP testing platform, creating an end-to-end analytical offering for biologics developers
Finance
Qureight raises $20m Series B to expand AI imaging platform into asthma, pulmonary hypertension and bronchiectasis

Qureight raises $20m Series B to expand AI imaging platform into asthma, pulmonary hypertension and bronchiectasis

The Molten Ventures-led round funds a 3D chest imaging Foundation Model laboratory and commercial expansion, building on Qureight's established lung fibrosis CRO capabilities across a $27.5bn clinical trials market.
Subscribe now